{"filing":{"accession_number":"0001104659-26-066623","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"tm2615712d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926066623/tm2615712d1_8k.htm"},"events":[{"id":8668,"run_id":7611,"accession_number":"0001104659-26-066623","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses a press release announcing Traws Pharma's antiviral program targeting Hantavirus and Ebola Virus disease outbreaks. This represents a material development in the company's pipeline or strategic focus that would be of interest to investors, but it does not fit neatly into the standard event categories (not an earnings release, M\u0026A activity, executive change, or other defined event type). The disclosure is material because it announces a significant new therapeutic program, but the specific nature of the announcement—a program targeting emerging infectious disease outbreaks—is best classified as other_material.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1808,"accession_number":"0001104659-26-066623","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release announcing Traws Pharma's antiviral program targeting Hantavirus and Ebola Virus disease outbreaks. This represents a material development in the company's pipeline or strategic focus that would be of interest to investors, but it does not fit neatly into the standard event categories (not an earnings release, M\u0026A activity, executive change, or other defined event type). The disclosure is material because it announces a significant new therapeutic program, but the specific nature of the announcement—a program targeting emerging infectious disease outbreaks—is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:11.039262+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1808,"accession_number":"0001104659-26-066623","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release announcing Traws Pharma's antiviral program targeting Hantavirus and Ebola Virus disease outbreaks. This represents a material development in the company's pipeline or strategic focus that would be of interest to investors, but it does not fit neatly into the standard event categories (not an earnings release, M\u0026A activity, executive change, or other defined event type). The disclosure is material because it announces a significant new therapeutic program, but the specific nature of the announcement—a program targeting emerging infectious disease outbreaks—is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:11.039262+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-05-27"}]}